Could this Healthcare Stock really climb 3,189.47% in 2024?

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Ad [Revolutionary Device Redefines Cancer Detection]( [Learn More Now - Before Anticipated FDA Approval in 2024]( --------------------------------------------------------------- March 4, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Ad [Digital Dollar: Freedom or Financial Slavery?]( a digital dollar really America’s way to financial freedom? Or is it the start of a wave of financial servitude? Get the details on the potential risks of a digital dollar and what you can do to protect yourself. From privacy concerns to economic control, protect yourself with this free guide. [Escape the digital dollar with this free guide]( --------------------------------------------------------------- [TRACON Pharmaceuticals, Inc.]( Symbol: [TCON]( Recent Price: $0.19 Average Analyst Price Target: $6.25 (3,189.47%) Market Cap: $5.86M Last Year's EPS: $-0.06 Consensus EPS Forecast: $-0.06 Expected Earnings Date: Mar 05, 2024 Recent Analyst Action: Edward White, analyst at H.C. Wainwright, reiterates coverage on [TRACON Pharmaceuticals, Inc. (TCON)]( in the Healthcare sector with a Buy rating and a price target of $7 (2 months ago). [TipRanks.com]( also reports that [TRACON Pharmaceuticals, Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $6.25 . The target pricing ranges from a high forecast of $7 down to a low forecast of $1. [TRACON Pharmaceuticals, Inc. (TCON)](’s last closing price was $0.19 which would put the average price target at 3,189.47% upside. Here are 3rd party ratings for [TCON](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 33% (82 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [Presto Automation, Inc.]( Symbol: [PRST]( Recent Price: $0.30 Average Analyst Price Target: $1.37 (357.78%) Market Cap: $24.24M Last Year's EPS: $0.08 Consensus EPS Forecast: $-0.22 Expected Earnings Date: Mar 05, 2024 Recent Analyst Action: Samad Samana, analyst at Jefferies, reiterates coverage on [Presto Automation, Inc. (PRST)]( in the Technology sector with a Hold rating and a price target of $0.62 (2 months ago). [TipRanks.com]( also reports that [Presto Automation, Inc.]( currently has 3 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $1.37 . The target pricing ranges from a high forecast of $2 down to a low forecast of $0.62. [Presto Automation, Inc. (PRST)](’s last closing price was $0.30 which would put the average price target at 357.78% upside. Here are 3rd party ratings for [PRST](: - TipRanks.com: Hold - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 34% (86 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [This New Tech Could Be Worth THREE TIMES the Entire New York Stock Exchange...]( believe this new tech will create more wealth than all the fortunes of the last 150 years combined. That’s why the world’s richest men and even the United States Senate approved throwing hundreds of BILLIONS of dollars into this new technology… [And right now, there’s a little-known stock at the center of all the action.]( In fact, this small-cap stock is still trading for less than it costs to buy a tank of gas. [Click here now for the whole story.]( --------------------------------------------------------------- [Bionano Genomics, Inc.]( Symbol: [BNGO]( Recent Price: $1.25 Average Analyst Price Target: $11.75 (840.00%) Market Cap: $48.55M Last Year's EPS: $-1.24 Consensus EPS Forecast: $-0.75 Expected Earnings Date: Mar 05, 2024 Recent Analyst Action: Mark Massaro, analyst at BTIG, reiterates coverage on [Bionano Genomics, Inc. (BNGO)]( in the Healthcare sector with a Buy rating and a price target of $6 (1 month ago). [TipRanks.com]( also reports that [Bionano Genomics, Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $11.75 . The target pricing ranges from a high forecast of $7 down to a low forecast of $14. [Bionano Genomics, Inc. (BNGO)](’s last closing price was $1.25 which would put the average price target at 840.00% upside. Here are 3rd party ratings for [BNGO](: - TipRanks.com: Buy - TradingView.com: Neutral - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Top 33% (82 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [CrowdStrike Holdings, Inc.]( Symbol: [CRWD]( Recent Price: $314.60 Average Analyst Price Target: $360.40 (14.56%) Market Cap: $75.55B Last Year's EPS: $0.74 Consensus EPS Forecast: $0.74 Expected Earnings Date: Mar 05, 2024 Recent Analyst Action: Andrew Nowinski, analyst at Wells Fargo, reiterates coverage on [CrowdStrike Holdings, Inc. (CRWD)]( in the Technology sector with a Buy rating and a price target of $380 (9 hours ago). [TipRanks.com]( also reports that [CrowdStrike Holdings, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $360.40 . The target pricing ranges from a high forecast of $380 down to a low forecast of $340. [CrowdStrike Holdings, Inc. (CRWD)](’s last closing price was $314.60 which would put the average price target at 14.56% upside. Here are 3rd party ratings for [CRWD](: - TipRanks.com: Buy - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Strong Buy, Top 23% (59 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- [Target Corporation]( Symbol: [TGT]( Recent Price: $155.29 Average Analyst Price Target: $162.40 (4.58%) Market Cap: $71.69B Last Year's EPS: $1.8 Consensus EPS Forecast: $1.48 Expected Earnings Date: Mar 05, 2024 Recent Analyst Action: Christopher Horvers, analyst at J.P. Morgan, reiterates coverage on [Target Corporation (TGT)]( in the Consumer Defensive sector with a Buy rating and a price target of $157 (3 days ago). [TipRanks.com]( also reports that [Target Corporation]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $162.40 . The target pricing ranges from a high forecast of $170 down to a low forecast of $157. [Target Corporation (TGT)](’s last closing price was $155.29 which would put the average price target at 4.58% upside. Here are 3rd party ratings for [TGT](: - TipRanks.com: Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 39% (99 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [Detecting Cancer in 1.5 Seconds: Early Investment Opportunity]( Stanford engineer's lofty goal of revolutionizing cancer diagnostics is expected to come to fruition with FDA review in its final stages. With a history of taking companies public, including a $2 billion market cap NASDAQ company, this may be his biggest venture yet! With the ability to detect cancer's "molecular fingerprint" in just 1.5 seconds, it also offers far superior accuracy to current detection methods! [Learn more about how this could transform the multi-billion dollar diagnostic market.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketMoverAlerts.com Disclaimer This email/newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this email/newsletter is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this email/newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our email/newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.[If you are not a human, click here.](By opening and/or clicking on any link contained within this email, you are reconfirming your opt-in status. You can unsubsubscribe at any time by clicking on the link in the footer. MarketMoverAlerts.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software